C4 Therapeutics, Inc. reported its financial results for the first quarter of 2026, revealing a revenue of $6.2 million from collaboration agreements, a decrease from $7.2 million in the same period last year. The decline in revenue is attributed primarily to a $1.4 million drop in revenue from the MKDG collaboration, as the company shifted its focus to a single KRAS project, and the termination of the Merck collaboration, which accounted for a $1.1 million decrease. The company continues to operate at a loss, posting a net loss of $25.1 million for the quarter, slightly improved from a net loss of $26.3 million in the first quarter of 2025.
Total operating expenses for the quarter were $33.9 million, down from $36.4 million year-over-year. Research and development expenses decreased to $24.6 million from $27.1 million, primarily due to reduced preclinical development costs following the termination of the Merck collaboration and a strategic decision to prioritize one project under the MKDG collaboration. General and administrative expenses remained stable at $9.3 million, reflecting consistent operational costs.
C4 Therapeutics' balance sheet as of March 31, 2026, showed total assets of $328.9 million, down from $359.1 million at the end of 2025. The decrease in assets was driven by a reduction in cash and cash equivalents, which fell to $61.3 million from $74.6 million. The company’s accumulated deficit increased to $763.8 million, highlighting the ongoing financial challenges faced as it continues to invest heavily in research and development without generating product sales.
Strategically, C4 Therapeutics has entered into several collaboration agreements, including a recent partnership with Roche to develop degrader-antibody conjugates, which could significantly enhance its product pipeline. The company is also advancing its lead candidate, cemsidomide, through clinical trials for multiple myeloma, with plans to initiate additional trials in the near future. Despite the current financial losses, C4 Therapeutics maintains a positive outlook, expecting its cash reserves and marketable securities of approximately $268.3 million to support operations for at least the next twelve months. The company continues to explore additional collaborations and funding opportunities to bolster its financial position and advance its clinical programs.
About C4 Therapeutics, Inc.
C4 Therapeutics is a clinical-stage biopharmaceutical company specializing in targeted protein degradation (TPD) to develop small-molecule medicines that eliminate disease-causing proteins. Leveraging its proprietary TORPEDO platform, the company designs oral, selective protein degraders primarily for oncology indications, including multiple myeloma, non-Hodgkin lymphoma, melanoma, colorectal, and non-small cell lung cancers. C4’s approach offers catalytic, durable, and highly selective therapies addressing unmet medical needs through innovative drug discovery and strategic collaborations.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.